PetVivo Holdings (PetVivo Holdings) ROCE % : -339.83% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is PetVivo Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PetVivo Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -339.83%.

PetVivo Holdings ROCE % Historical Data

The historical data trend for PetVivo Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetVivo Holdings ROCE % Chart

PetVivo Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-177.94

-241.28

PetVivo Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-488.21	-937.22	-884.00	-774.19	-339.83

PetVivo Holdings ROCE % Calculation

PetVivo Holdings's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-8.733	/	( ( (7.427 - 1.173)	+	(2.439 - 1.454) )	/ 2 )
	=	-8.733	/	( (6.254	+	0.985)	/ 2 )
	=	-8.733	/	3.6195
	=	-241.28 %

PetVivo Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-6.992	/	( ( (4.062 - 1.915)	+	(3.63 - 1.662) )	/ 2 )
	=	-6.992	/	( ( 2.147	+	1.968 )	/ 2 )
	=	-6.992	/	2.0575
	=	-339.83 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

PetVivo Holdings (OTCPK:PETV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PetVivo Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PetVivo Holdings (PetVivo Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5251 Edina Industrial Boulevard, Edina, MN, USA, 55439

Website

https://www.petvivo.com

PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.

Executives

James Rudolph Martin	director	POBOX 53988, IRVINE CA 92619
A.l. Sarroff Fund, Llc	10 percent owner	43 MEADOW WOODS ROAD, GREAT NECK NY 11020
John Spencer Breithaupt	director	3041 W. PASADENA DR., BOISE ID 83705
Robert J Costantino	director	5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Joseph William Jasper	director	201 SOUTH 11TH STREET, UNIT 1030, MINNEAPOLIS MN 55403
John Lai	director, 10 percent owner, officer: CEO	12100 SINGLETREE LANE, SUITE 186, EDEN PRAIRIE MN 55344
Robert James Rudelius	director	6913 ARBOR LANE, MCCLEAN VA 22101
Leslie Anne Coolidge	director	345 OLD SUTTON ROAD, BARRINGTON HILLS IL 60010
Robert J. Folkes	officer: Chief Financial Officer	1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Scott Mitchell Johnson	director	475 LAKESHORE UNIT #32, INCLINE VILLAGE NV 89451
James Joseph Martin	director	4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Gregory D Cash	director
John Michael Carruth	officer: Acting Chief Financial Officer	4923 RIVER WOOD DR., SAVAGE MN 55439
Sherry Grisewood	director	377 FAIRMOUNT ROAD, CALIFON NJ 07830
David Don Deming	director	16200 45TH STREET SOUTH, AFTON MN 55001